Related Experiment Video
Updated: Aug 10, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Interspecies differences in thromboxane A2 receptors are distinguished by glibenclamide
1Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
European Journal of Pharmacology
|October 1, 1998
Summary
The thromboxane A2 receptor antagonist GR32191 potently inhibited U46619 contractions in rat and guinea-pig arteries. Glibenclamide selectively antagonized U46619 in rat arteries, suggesting species-specific effects on thromboxane A2 receptors.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
- Drug Discovery
Background:
- Thromboxane A2 (TXA2) is a potent mediator of vasoconstriction.
- TXA2 receptor antagonists are investigated for cardiovascular conditions.
- Glibenclamide, a sulfonylurea, has shown unexpected vascular effects.
Purpose of the Study:
- To compare the efficacy of GR32191 and glibenclamide as TXA2 receptor antagonists.
- To investigate species-specific differences in TXA2 receptor antagonism.
- To elucidate the mechanism of glibenclamide's action on TXA2-mediated contractions.
Main Methods:
- Isolated rat and guinea-pig arteries (aorta, mesentery, coronary) were used.
- Concentration-response curves for U46619 were generated.
- Antagonism was assessed in the presence of GR32191 and glibenclamide.
- pKB values were calculated to quantify antagonist potency.
Main Results:
- GR32191 was a potent antagonist in both species, with higher potency in guinea-pig vessels (pKB ~9.4) than rat arteries (pKB ~7.9).
- Glibenclamide antagonized U46619 in rat aorta (pKB = 6.1) and mesenteric artery (pKB = 6.3) but not in guinea-pig vessels.
- Combined GR32191 and glibenclamide showed additive effects in rat aorta.
Conclusions:
- GR32191 is a potent TXA2 receptor antagonist across species.
- Glibenclamide exhibits species-specific antagonism of TXA2 receptors, primarily in rats.
- Glibenclamide's inhibitory effect on U46619-induced contractions likely occurs at the TXA2 receptor level.
More Related Videos
Related Concept Videos
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...